OncoMatch/Clinical Trials/NCT06764238
Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
Is NCT06764238 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2/3 trial studies multiple treatments including Blinatumomab (Group A) and Venetoclax (nonRand Group) for acute lymphoblastic leukemia all.
Treatment: Blinatumomab (Group A) · Venetoclax (nonRand Group) · Blinatumomab (Group B) — Building upon the results from the CCCG-ALL-2015, CCCG-ALL-2020 multicenter study cohort, concurrent research findings, and the latest clinical trials, the CCCG-ALL-2025 I/HR-B-ALL is thus developed to further improve the event-free survival (EFS), and overall survival (OS), and quality of life (QoL) of children with intermediate- and high- risk B-cell childhood acute lymphoblastic leukaemia (I/HR-B-ALL), while decreasing adverse reactions and transplantation rates. This trial primarily aims to explore: 1. The efficacy of two randomized Blinatumomab application scheme on I/HR-ALL as determined by MRD negatvitiy rate. 2. The efficacy of modified mini-hyperCVD + Venetoclax in I/HR-ALL cannot afford blinatumomab, in contrast to historical control as determined by MRD negatvitiy rate.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Lymphoblastic Leukemia
Disease stage
Required: Stage INTERMEDIATE RISK, HIGH RISK
Excluded: Stage LOW-RISK
Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol; Low-risk ALL [excluded]
Demographics
Prior therapy
Cannot have received: glucocorticoid
Treated with glucocorticoids for ≥14 days within one month before enrollment
Cannot have received: ABL kinase inhibitor
ABL kinase inhibitors for > 7 days within one month before enrollment
Cannot have received: chemotherapy
any chemotherapy within 3 months before enrollment
Cannot have received: radiotherapy
Exception: emergency radiotherapy to relieve airway compression
any radiotherapy within 3 months before enrollment (except for emergency radiotherapy to relieve airway compression)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06764238 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage INTERMEDIATE RISK or HIGH RISK is required.
Is there an age limit?
Yes. Patients must be 18 years or younger and at least 0 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages